Steven B Ruchefsky insider trades: Kite Pharma (KITE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Steven reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 14, 2017 | KITE | ↓ Sell | 20,000 | $89.48 | $1.8M | Direct | Jun 16, 2017 (2d) |
| May 9, 2017 | KITE | ↑ Buy | 1,400 | $69.50 | $97K | Direct | May 10, 2017 (1d) |
| Jan 12, 2016 | ARNI | ↑ Buy | 2,876,633 | $0.35 | $1.0M | By Commercial Street Capital, LLC | Jan 14, 2016 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Steven B Ruchefsky's insider trades
Steven B Ruchefsky is a director at Kite Pharma (KITE). Since Jan 12, 2016, Steven has reported 2 open-market purchases worth $1.1M and 1 sale worth $1.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), other transactions (4 filings), shares returned to the company (3 filings), conversions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KITE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.